HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.

HRDetect (WGS mutational signature score) refines HRD/HRP classification beyond germline or somatic BRCA status

HRDetect, a WGS mutational signature-based algorithm, was evaluated in 185 patients with advanced ovarian cancer (UW cohort) and validated in 77 rucaparib-treated patients (ARIEL2). HRDetect stratifies patients into distinct prognostic subgroups beyond germline/somatic BRCA status and correlates with PARP inhibitor response. Non-BRCA HRD patients are identified as potential beneficiaries, expanding the PARP inhibitor target population.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

HRDetect represents a concrete step toward identifying non-BRCA HRD patients who could benefit from PARPi — a population currently excluded from approved indications. Routine clinical WGS in ovarian cancer remains the main bottleneck, but these data strengthen the argument for tumor-normal WGS pilot programs in oncogenetics.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 2/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 8/10